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ABSTRACT:
We previously reported an ontogeny model of hepatic cytochrome
P450 (P450) activity that predicts in vivo P450 elimination from in
vitro intrinsic clearance. The purpose of this study was to conduct
investigations into key assumptions of the P450 ontogeny model
using the developing rat model system. We used two developmen-
tally dissimilar enzymes, CYP2E1 and CYP1A2, and male rats (n 
4) at age groups representing critical developmental stages. Total
body and liver weights and hepatic microsomal protein contents
were measured. Following high-performance liquid chromatogra-
phy analysis, apparent KM and Vmax estimates were calculated
using nonlinear regression analysis for CYP2E1- and CYP1A2-
mediated chlorzoxazone 6-hydroxylation and methoxyresorufin
O-dealkylation, and Vmax estimates for p-nitrophenol and phenac-
etin hydroxylations, respectively. Hepatic scaling factors and Vmax
values provided estimates for infant scaling factors (ISF). The data
show microsomal protein contents increased with postnatal age
and reached adult values after postnatal day (PD) 7. Apparent KM
values were similar at all developmental stages except at <PD7.
Developmental increases in probe substrate Vmax values did not
correlate with the biphasic increase in immunoquantifiable P450.
The activity of two different probe substrates for each P450 covar-
ied as a function of age. A plot of observed ISF values as a function
of age reflected the developmental pattern of rat hepatic P450. In
summation, these observations diverge from several of the mod-
el’s assumptions. Further investigations are required to explain
these inconsistencies and to investigate whether the developing
rat may provide a predictive paradigm for pediatric risk assess-
ment for P450-mediated elimination processes.
Intentional and inadvertent exposures (i.e., environmental contam-
ination, breast milk) of the developing neonate to xenobiotics raises
significant concerns over the potential risks posed to the exposed
neonate. However, ethical impediments and limited toxicity data in
human pediatric populations hinder the assessment of such risk.
Furthermore, evidence for age-dependent differences in susceptibility
to toxicity precludes a simple adult-to-neonate extrapolation of tox-
icity risk based upon toxicology studies in adult populations (Clark et
al., 2004; Ginsberg et al., 2004b). A need exists, then, for predictive
paradigms for risk assessment in human pediatric populations.
Pharmacokinetic processes, particularly elimination mechanisms,
often underlie these age-related differences in susceptibility to toxic-
ity. Most elimination processes undergo significant ontogeny (Alcorn
and McNamara, 2002a) and their maturation status in the developing
neonate may determine toxicological outcomes following a xenobiotic
exposure (Ginsberg et al., 2004a; Barton, 2005). Consequently,
knowledge of a neonate’s elimination capacity is critical for toxico-
logical risk assessments. To address this issue, recent efforts to use
available data on the ontogeny of xenobiotic elimination mechanisms
in humans and animals have lead to models that allow predictions of
xenobiotic elimination in the developing neonate (Alcorn and Mc-
Namara, 2002b; Brent, 2004; Barton, 2005; Jarabek et al., 2005;
Bjorkman, 2006; Edginton et al., 2006; Johnson et al., 2006; Nong et
al., 2006) These models are either based upon physiological data from
pediatric patients and adults or upon developmental toxicological
assessments in suitable animal systems. In the only validated model
approach (Nong et al., 2006), the authors reported that a physiologi-
cally based pharmacokinetic model premised upon knowledge of age-
and subject-specific human CYP2E1 protein content and known phys-
iological variables can be used to evaluate interindividual variation in
internal dosimetry estimates for toluene (CYP2E1 substrate) expo-
sures in children and represents a feasible approach for risk assess-
This work was supported by the Natural Sciences and Engineering Research
Council of Canada Grant 261219. This study was presented in part at the Seventh
International ISSX Meeting, Vancouver, BC, Canada, 2004, and at the Eighth
Annual Canadian Society for Pharmaceutical Sciences, Toronto, ON, Canada,
2005, and it was published in part in abstract form in Drug Metab Rev 36(Suppl
1):340.
A small amount of data in this article was recently published in Elbarbry FA,
McNamara PJ, and Alcorn J (2007) Ontogeny of hepatic CYP1A2 and CYP2E1
expression in rat. J Biochem Mol Toxicol 21:41–50, Fig. 3. Rights to use this data
have been granted by John Wiley & Sons, Inc.
Article, publication date, and citation information can be found at
http://dmd.aspetjournals.org.
doi:10.1124/dmd.107.017590.
ABBREVIATIONS: P450, cytochrome P450; CZX, chlorzoxazone; 6-OH CZX, 6-hydroxychlorzoxazone; PNP, p-nitrophenol; 4NC, p-nitrocatechol;
HRP, horseradish peroxidase; MROD, methoxyresorufin O-dealkylation; HPLC, high-performance liquid chromatography; PBS, phosphate-
buffered saline; PBSt, phosphate-buffered saline/Tween 20; HSF, hepatic scaling factor; ISF, infant scaling factor(s); PD, postnatal day; MP,
microsomal protein.
0090-9556/07/3512-2225–2231$20.00
DRUG METABOLISM AND DISPOSITION Vol. 35, No. 12
Copyright © 2007 by The American Society for Pharmacology and Experimental Therapeutics 17590/3279079
DMD 35:2225–2231, 2007 Printed in U.S.A.
2225
 at A
SPET Journals on January 4, 2017
dm
d.aspetjournals.org
D
ow
nloaded from
 
ment purposes. Predictions of xenobiotic elimination capacity alone,
though, offer little understanding on mechanisms of toxicity and
mitigating genetic and environmental factors contributing to interin-
dividual variation in toxicity. To facilitate our understanding of age-
dependent differences in susceptibility to toxicity an appropriate de-
velopmental animal model system remains mandatory (Graeter and
Mortensen, 1996; Koren et al., 2003; Brent, 2004).
Our laboratories previously developed an ontogeny model of he-
patic P450-mediated elimination based on an in vitro-in vivo extrap-
olation of published P450 activity data from age-specific human fetal
and infant hepatic microsomes. Our review outlines the theoretical
framework for the model (Alcorn and McNamara, 2002b). Briefly, the
model involves scaling in vitro hepatic intrinsic clearance data to in
vivo intrinsic clearance and the extrapolation of known adult intrinsic
clearance values to any age during postnatal development. This ex-
trapolation occurs via a scaling factor (the infant scaling factor),
which incorporates age-dependent changes in hepatic scaling factors
and P450 activity. Critical assumptions of the model include 1)
microsomal protein content is constant and independent of develop-
mental age; 2) KM values are constant and not a function of devel-
opmental age; 3) Vmax is proportional to functional enzyme level and
activity from one substrate will accurately predict activity for all
substrates of that enzyme; 4) uptake and efflux transporters do not
contribute significantly to intrinsic clearance; 5) the drug is a low
extraction ratio drug; and 6) the elimination pathways in the adult are
known and the infant shares the same pathways.
Since interspecies extrapolation of developmental toxicity data
remains a practical option to elucidate the impact of development on
susceptibility to toxicity, we propose a similar model approach for rat
hepatic P450 ontogeny as a means of providing a predictive paradigm
for risk assessment. Comparative analyses of human and rat P450
enzyme maturation (Cresteil, 1987; Rich and Boobis, 1997) and P450
enzyme substrate specificity and regulation highlight important spe-
cies differences between the rat and human. Furthermore, differences
in the rates and patterns of P450 maturation (Alcorn and McNamara,
2002a) may result in species differences in the parameterization of the
model. Nevertheless, P450 enzyme mechanisms are similar across
species, which suggests model assumptions remain the same regard-
less of species. However, before any toxicokinetic model of P450
ontogeny in rat can be developed and used to provide robust predic-
tions of hepatic P450-mediated elimination, we must first evaluate the
appropriateness of the model’s underlying assumptions.
The purpose of this study is to conduct investigations into the key
assumptions of the model of hepatic P450 ontogeny. We use two
developmentally dissimilar P450 enzymes, CYP2E1 and CYP1A2,
and male Sprague-Dawley rats at various fetal, neonatal, juvenile, and
adult age groups to provide critical information on the assumptions of
the model. The implications of the findings on the validity of the
model are discussed.
Materials and Methods
Chemicals and Reagents. Chlorzoxazone (CZX), 6-hydroxychlorzoxazone
(6-OH CZX), umbelliferone (7-hydroxycoumarin), p-nitrophenol (PNP), p-
nitrocatechol (4NC), salicylamide, phenacetin, acetaminophen, caffeine,
resorufin, methoxyresorufin, and all chemicals used for microsomal prepara-
tion, determination of microsomal protein content, and enzyme assays were
purchased from Sigma-Aldrich Canada Ltd. (Oakville, ON, Canada). Rat
CYP1A2 and CYP2E1 supersomes were acquired from BD Biosciences
(Woburn, MA). Peroxidase-conjugated antibody (goat anti-rabbit IgG HRP
conjugate), prestained SDS-polyacrylamide gel electrophoresis standards, Im-
mun-Star HRP kit, and Trans-Blot cell and polyvinylidene diflouride mem-
branes (0.2 m) were obtained from Bio-Rad (Hercules, CA). Rabbit anti-
human/rat CYP2E1 and sheep anti-rat CYP1A2 polyclonal antibodies and
rabbit anti-sheep IgG HRP conjugate antibody were purchased from Chemicon
International (Temecula, CA). All other chemicals used were analytical grade.
Animals. Sprague-Dawley rats were obtained from Charles River Canada
(St. Constant, PQ, Canada). Eight pregnant rats were received at day 14 of
pregnancy and allowed to acclimatize for 1 week. At day 21 of pregnancy, four
pregnant rats were anesthetized under isoflurane, and the fetuses were col-
lected. Given the difficulty with sex-typing fetal rats, pups from both genders
were used. The remaining pregnant rats were allowed to give birth, and one
male pup from each dam was collected at postnatal ages 1, 3, 5, 7, and 10 days.
Other age groups (2, 3, 4, 6, 9, 12, and 16 weeks) (n  4) were obtained from
Charles River Canada 1 week before the required age during which time rats
were allowed to acclimatize. All rats received standard laboratory rat chow and
water ad libitum throughout the acclimatization period. At the appropriate age,
body weights were recorded. Rats were then killed by guillotine under light
isoflurane anesthesia, and the livers were rapidly excised and rinsed in cold
0.9% NaCl. Livers were then weighed and flash frozen in liquid nitrogen and
stored at 80°C until microsomal preparation. All procedures were conducted
in accordance with the Canadian Council of Animal Care guidelines for the
care and use of laboratory animals, and they were approved by the Animal
Care and Supply Committee of the University of Saskatchewan (Saskatoon,
SK, Canada).
Preparation of Hepatic Microsomes. Hepatic microsomes were prepared
as described previously (Elbarbry et al., 2007). Protein concentrations of
microsomal preparations were determined in triplicate by the method of Lowry
et al. (1951) using bovine serum albumin as a calibration standard.
Microsomal Incubations with CYP2E1 and CYP1A2 Probe Substrates.
Preliminary experiments in 50-day-old male rat hepatic microsomes were
conducted to determine the optimum incubation conditions (incubation time
and microsomal protein content) to give linear metabolite formation kinetics
for CYP2E1-mediated hydroxylation of CZX and PNP and CYP1A2-mediated
phenacetin O-dealkylation and methoxyresorufin O-dealkylation (MROD) ac-
tivities. Michaelis-Menten parameters KM and Vmax for CYP2E1 and CYP1A2
were determined by measuring metabolite formation velocities of CZX and
MROD at substrate concentrations of 0 to 1000 M and 0 to 1000 nM,
respectively. With PNP and phenacetin, metabolite formation velocities were
measured at saturating probe substrate concentrations (500 and 150 M,
respectively) in age-specific rat hepatic microsomes to provide estimates of
Vmax.
HPLC Analysis. For CYP2E1, 6-hydroxylation of chlorzoxazone in rat
hepatic microsomal preparations was quantified using an HPLC analysis as
described previously (Elbarbry et al., 2007). For the second probe substrate,
PNP hydroxylation (CYP2E1 probe) was assayed as reported previously
(Elbarbry et al., 2006). Calibration curves were constructed from known
concentrations of 6-OH CZX and 50 l of the internal standard (0.078 mM
umbelliferone) or known concentrations of 4-nitrocatechol and 50 l of
internal standard (6 g/ml salicylamide) added to heat-inactivated (55°C for 5
min) rat hepatic microsomes. The calibration standards were diluted with 50
mM phosphate buffer, pH 7.4, to achieve calibration standards of 0.31 to 40
M for 6-OH CZX or 0.1 to 40 M for 4NC in a total volume of 0.5 ml. Three
quality control samples at 0.625 M (low), 1.25 M (medium), and 5 M
(high) for 6-OH CZX or 0.5 M (low), 5 M (medium), and 20 M (high) for
4NC were prepared independently of those used for the calibration curves.
Coefficients of determination were greater than 0.999 for all calibration curves.
Intraday and interday precisions were less than 14%. The accuracy of esti-
mated metabolite concentrations ranged from 91 to 113%.
For CYP1A2, phenacetin O-dealkylation (CYP1A2 probe) was assayed by
a published HPLC method (von Moltke et al., 1996) using caffeine as an
internal standard. UV absorbance was monitored at 254 nm (max for acet-
aminophen). The mobile phase consisted of 50 mM potassium dihydrogen
phosphate and acetonitrile at a ratio of 85:15 [v/v (%)], and it was delivered at
1.0 ml/min. Calibration curves were constructed from known concentrations of
resorufin or acetaminophen, and the internal standard (5 g/ml caffeine) was
added to heat-inactivated (55°C for 5 min) rat hepatic microsomes and diluted
with 50 mM phosphate buffer, pH 7.4, to achieve calibration standards of 0.04
to 2 nM for resorufin and 0.2 to 20 M for acetaminophen in a total volume
of 0.5 ml. Three quality control samples at 0.1 nM (low), 0.4 nM (medium),
and 2 nM (high) for resorufin and 0.5 M (low), 2 M (medium), and 10 M
(high) for acetaminophen were prepared independently of those used for the
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calibration curves. Coefficients of determination were greater than 0.999 for
all calibration curves. Intra- and interday precision was 14 and 9% for
resorufin and acetaminophen, respectively, and accuracy was within 15% of
the nominal value for both HPLC assays.
CYP1A2 and CYP2E1 Protein Quantification. Hepatic microsomal pro-
teins were separated on a sodium dodecyl sulfate gel containing 10% poly-
acrylamide (SDS-polyacrylamide gel electrophoresis) by standard methods.
The gel was loaded with rat CYP1A2 purified protein (20, 80, 200, and 500
pmol) or heat-denatured microsomes (0.4 g of protein) for CYP1A2 and rat
CYP2E1 purified protein (20, 50, and 100 pmol) or heat-denatured micro-
somes (10.5 g of protein) for CYP2E1, and electrophoresis was conducted for
1.5 to 2 h at 125 V. Proteins were transferred onto a polyvinylidene difluoride
membrane (0.2 m) with a Trans-Blot cell (Bio-Rad) at 25 V for 50 min. The
membrane was washed with phosphate-buffered saline (PBS) containing
0.05% Tween 20 (PBSt) and subsequently blocked with PBSt containing 5%
milk with overnight incubation at 4°C. For CYP1A2, the membrane was then
incubated overnight at 4°C with sheep anti-rat CYP1A2 polyclonal antibody
prepared in PBS solution (1:1000 dilution). For CYP2E1, the membrane was
incubated for 3 h at 20°C with rabbit anti-human/rat CYP2E1 polyclonal
antibody prepared in the blocking solution (1:750). Following the appropriate
incubation period, membranes were washed three times with PBSt and once
with PBS, and then they were incubated with peroxidase-conjugated antibody
prepared in the blocking solution (1:3000) for 2 h at 20°C. The membrane was
further washed three times with PBSt and once with PBS, and then immuno-
detection was performed using the Immun-Star HRP kit. To estimate the
amount of reacting protein, the blot was scanned with an LKB laser densi-
tometer (GE Healthcare, Piscataway, NJ) using reference samples to calibrate
determinations. The results were expressed as absorbance unit per microgram
of protein (optical density per microgram of protein).
Scaling Factors. Hepatic scaling factors for a particular age [HSF(t)] were
estimated from the product of microsomal protein yield [MP(t)] (milligrams of
microsomal protein per gram of liver) and liver weight (grams) [LW(t)]
normalized to body weight (grams) [BW(t)] as a function of developmental age,
t, according to eq. 1:
HSFt  MPt 
LWt
BWt
(1)
Infant scaling factors at a particular age, t [ISF(t)] were estimated from the
product of HSF(t) and Vmax values at the same age, t [Vmax,(t)] normalized to the
product of the respective adult values according to eq. 2:
ISFt 
HSF tinfantV Max,tinfant
HSFadultV Maxadult
(2)
Data Analysis. All data within the same age was reported as mean  S.D.
Metabolite formation velocity as a function of substrate concentration was fit
to a one-enzyme site Michaelis-Menten equation. The parameters Vmax and KM
were estimated by an iterative nonlinear least-squares regression analysis using
GraphPad Prism 3.0 (GraphPad Software Inc., San Diego, CA). Significant
differences in total microsomal protein content, P450 protein content, and Vmax
and KM estimates between the different age groups were assessed with one-
way analysis of variance with Tukey’s post hoc test for pairwise multiple
comparisons using GraphPad Prism. For CZX KM estimates a Wilcoxon signed
rank test was used for pooled data. Pearson correlation coefficients were
determined to compare the Vmax values of two different substrates of the P450.
The level of significance was set at P  0.05.
Variation associated with the computed ISF(t) values was represented as a
coefficient of variation according to eq. 3, where X is the infant ISF mean value,
Y is the adult ISF mean value, X/Y is the ratio of the mean infant ISF to the mean
adult ISF values, S.D. is the standard deviation, and n is the sample size.
CVX/Y  SD/nX Infant
2
 SD/nY Adult
2
(3)
Results
HSF as a Function of Developmental Age. To evaluate whether
microsomal protein content remains constant with developmental age
(the first major assumption of the ontogeny model of P450 enzyme
activity), we measured total body and liver weights and liver micro-
somal protein content (milligrams per gram of liver) in fetal (gestation
day 20), neonatal, juvenile, and adult age groups (Table 1). As
expected, mean total body and liver weights increased with postnatal
age, with the most prominent increases occurring during puberty
(PD42–PD63). The age-dependent increase in liver and body weights
was associated with marked interindividual variation, which reflects
the normal variation in rates and patterns of body and organ growths
typically observed in animal species. The average microsomal protein
content per gram of liver (MP) was significantly lower than adult
levels in fetal and early postnatal age groups. After PD5, MP levels
were similar to adult values.
Closer examination of the data showed mean liver weight normal-
ized to total body weight remained relatively constant with postnatal
age. The pattern observed in the mean HSF values with age (Fig. 1)
mirrored the developmental pattern of microsomal protein content per
gram liver (Table 1). HSF values between gestational day 20 and
postnatal day 5 remained approximately at 50 to 70% of the adult
value. HSF values steadily increased to reach 	2-fold the adult value
by PD42. By PD63, mean HSF values were similar to adult values.
KM as a Function of Development. To evaluate whether KM
values remain constant with developmental age (the second major
assumption of the ontogeny model of P450 enzyme activity) we
conducted enzyme kinetic studies in rat hepatic microsomes with
probe substrates specific for CYP2E1 and CYP1A2, namely, CZX
and methoxyresorufin, respectively. For CYP2E1, limited tissue avail-
ability necessitated the use of pooled microsomes (pooled from four
animals). We detected no activity in gestation day 20 and PD1 hepatic
microsomes, and CZX apparent KM values were significantly lower
than adult values (35–40% of adult values) at PD3 and PD5 (data not
shown). By PD10, apparent KM values were similar to adult values,
and they stayed relatively constant thereafter.
For CYP1A2, the apparent KM estimates for MROD for PD5 and
PD7 were significantly higher than adult values (
2.5-fold adult
values) (Fig. 2). No significant differences in apparent KM estimates
were observed for PD age groups 10 days. The data did not allow
estimation of KM values in fetal, PD1, and PD3 age groups, although
activity was detected at low levels at PD3.
TABLE 1
Mean  S.D. total body and liver weights (grams) and hepatic microsomal
protein content (milligrams per gram of liver) for male Sprague-Dawley rats
(n  4) at different pre- and postnatal ages
Significant life stages in relation to age groups reported in the table are average gestation
period, 22 days; weaning, 21–28 days; puberty, 42–63 days; and adult, 112 days (life stage
information provided by Charles River Canada).
Age Total Body Wt. Liver Wt. Microsomal Protein
g mg/g liver
Fetusa 2.69 (0.58)b 0.21 (0.055)b 5.71 (2.3)b
1 day 7.09 (0.46)b 0.32 (0.077)b 9.40 (3.2)b
3 days 9.40 (0.82)b 0.42 (0.070)b 14.7 (3.8)b
5 days 12.9 (1.4)b 0.53 (0.096)b 15.7 (6.8)b
7 days 17.4 (1.3)b 0.63 (0.089)b 20.6 (4.0)
10 days 26.2 (4.3)b 0.86 (0.34)b 22.3 (4.4)
14 days 32.7 (3.1)b 1.13 (0.24)b 27.3 (4.7)
21 days 59.4 (4.8)b 2.62 (0.24)b 36.4 (14.1)
28 days 105 (6.3)b 4.93 (0.54)b 39.2 (14.0)
42 days 203 (12.1)b 9.39 (0.75)b 43.1 (15.3)
63 days 399 (30.5)b 16.2 (2.6) 36.0 (10.9)
84 days 411 (9.6)b 13.8 (0.51) 41.3 (6.9)
112 days 507 (27.3) 15.0 (1.4) 32.4 (7.3)
a Fetuses were collected at 20 days gestation from three dams and the fetal livers obtained
from a single dam were pooled for microsomal preparation.
b Statistically significant from adult (112 days); P  0.05.
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Vmax as a Function of Development. To assess whether enzyme
activity (Vmax) is proportional to enzyme level during ontogeny (the
third major assumption of the ontogeny model of P450 enzyme
activity), we measured CYP1A2 and CYP2E1activity at saturating
probe substrate concentrations in rat hepatic microsomes at different
developmental stages, and we compared this activity to immunoquan-
tifiable P450 levels at the same developmental age. MROD activity
(Fig. 3A) was first detected at PD3, but it was below the level of
quantification of the HPLC assay. PD5 and PD7 hepatic microsomes
demonstrated significantly lower MROD activity at 11 and 20% adult
activity, respectively. MROD activity increased significantly to reach
	1.75-fold the adult values by PD28. However, after weaning (PD28)
and during puberty (PD42–PD63) Vmax values fell to adult values.
Although the marked increase in MROD activity between PD14 and
PD21 corresponded to a marked increase in age-dependent hepatic
scaling factors (Fig. 1), activity declined after PD28 to the adult value
by PD42, unlike the hepatic scaling factor.
We did not detect CZX hydroxylase activity (Fig. 3B) in fetal and
PD1 livers. CZX hydroxylase activity was first detected in PD3 livers
(70% of the adult value), which increased significantly to reach
maximum levels by PD14 (	1.6-fold adult value) and generally
declined thereafter to adult values. The marked postnatal increase in
Vmax values for CZX hydroxylase preceded hepatic scaling factor
values, where the predominant age-dependent increase occurred be-
tween PD14 and PD21 and continued to increase until PD42 (Fig. 1).
Immunoquantifiable CYP1A2 and CYP2E1 exhibited a biphasic
pattern of development (Fig. 4). Rapid increases in immunodetectable
levels of CYP1A2 and CYP2E1 occurred during the early postnatal
period (PD7) followed by a slower, more gradual increase to adult
values. The rapid rise in immunodetectable CYP1A2 and CYP2E1 in
the early postnatal period seemed to parallel increases in MROD and
CZX hydroxylase activity. Thereafter, a marked discordance between
P450 protein and activity was observed, and Vmax values did not
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FIG. 1. Mean  S.D. hepatic scaling factors in male Sprague-Dawley rats (n  8,
except PD84 where n  4) as a function of postnatal age. Hepatic scaling factors
were calculated from the product of microsomal protein content (milligrams per
gram of liver) and total wet liver weight (grams) normalized to total body weight
(grams) [see eq. 1; asterisks indicate statistical difference from adult (112 days);
P  0.05].
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FIG. 2. Michaelis-Menten constant (KM) estimates for MROD activity (CYP1A2
marker) as a function of developmental age in male Sprague-Dawley rat hepatic
microsomes (n  4). The asterisk refers to those age groups that show significant
difference from adult; P  0.05. Activity was detected at PD3, but the data did not
allow for apparent KM estimation.
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FIG. 3. Vmax estimates for MROD activity (CYP1A2 marker) (A) and CZX hy-
droxylase activity (CYP2E1 marker) (B) as a function of developmental age in male
Sprague-Dawley rat hepatic microsomes. The data are expressed as mean  S.D. of
four rats. The asterisk refers to those age groups that show significant difference
from adult.
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correlate (Pearson r  0.35, P 
 0.05 for CYP1A2; Pearson r 
0.08, P 
 0.05 for CYP2E1) with changes in immunoquantifiable
levels observed in the same age group (Fig. 4).
To determine whether enzyme activity (Vmax) from one substrate
will accurately predict the level of activity for all substrates of the
enzyme, we correlated the Vmax values at each age group from one
P450 probe substrate with the second probe substrate (Fig. 5). Figure
5 suggests a strong and significant correlation between the activity of
one specific substrate relative to a second specific substrate for both
CYP1A2 (r  0.68, P  0.05; data not shown due to low variability
in the phenacetin O-dealkylation data relative to the MROD data) and
CYP2E1 (r  0.69, P  0.05).
Figure 6 shows the postnatal developmental pattern of CYP1A2
and CYP2E1 when scaled to the whole body. For both P450 enzymes,
whole body P450 activity is low at birth and rapidly increases to
maximum levels at the end of weaning (PD28). Thereafter, whole
body P450 activity declines toward adult values by the end of puberty
(PD63).
Discussion
The very limited toxicological data in human pediatric populations
prompted efforts to advance physiologically based pharmacokinetic
models in animal developmental toxicology systems for human pedi-
atric risk assessments (Brent, 2004; Clark et al., 2004). By relating
xenobiotic elimination capacity to the time course of P450 maturation,
the previously reported ontogeny model of P450 activity (Alcorn
and McNamara, 2002b) contributes to such efforts. A valid and
robust model can facilitate study design and dosage selection for
developmental toxicology studies and identify when age-depen-
dent differences in xenobiotic elimination account for differences
in susceptibility to toxicity. To this end, we evaluated the under-
lying assumptions of the P450 ontogeny model (Alcorn and Mc-
Namara, 2002b) in a toxicologically relevant animal system. The
assessments in the rat identified important departures from model
assumptions, and we discuss their possible underlying causes and
overall significance below.
Hepatic Scaling Factor. In vitro-in vivo extrapolation of intrinsic
clearance data requires knowledge of developmental changes in mi-
crosomal protein content, liver weight, and body weight (Carlile et al.,
1997; Houston and Carlile, 1997; Obach et al., 1997). In the human
P450 ontogeny model, we obtained information on the age-dependent
changes in liver and body weight from the literature, but we assumed
hepatic microsomal protein content on a per gram liver basis remained
constant throughout postnatal development and used a published
literature value (Alcorn and McNamara, 2002b). Any age-related
changes in hepatic scaling factors, then, became dependent solely on
developmental changes in liver weight normalized to body weight.
In this study, rat hepatic microsomal protein content per gram liver
increased significantly during the neonatal period, reached a maxi-
mum at puberty and declined to adult levels in the early postpubertal
stage. The data are consistent with rat hepatic microsomal content
described in a limited number of postnatal, prepubertal, and pubertal
age groups and adults in the literature (Borlakoglu et al., 1993; Kishi
et al., 2005). Postnatal changes in microsomal protein content in the
rat suggest a need for similar investigations with human pediatric
livers (Johnsrud et al., 2003; Johnson et al., 2006). Interestingly, the
age-dependent changes in rat hepatic scaling factors became a func-
tion of changes in microsomal protein content rather than liver
weight-to-body weight ratio, which stayed relatively constant and
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independent of developmental stage. Although these findings contra-
dict a model assumption, this contradiction does not necessarily
weaken its potential value. These results merely suggest the need to
measure hepatic microsomal protein content in pediatric livers to
incorporate its developmental change into the modeling process to
provide predictive estimates of the infant scaling factors.
Clearance as a Function of Hepatic Metabolic Enzyme Activity.
The ontogeny model makes the limiting assumption that systemic
clearance is a function of hepatic metabolic enzyme activity (i.e., the
xenobiotic is a low hepatic extraction ratio compound) and uptake and
efflux transporters make no contribution to intrinsic clearance. We
used probes (Kobayashi et al., 2002) that are known low hepatic
extraction ratio compounds, but these probes have not been assessed
as transporter substrates. Intrinsic clearance estimates are affected by
substrates where membrane transporters act as a rate-limiting process
of metabolic clearance (Ito et al., 1998). At present, the model makes
no accommodation for such substrates, but it has the potential to
incorporate transport processes in the infant scaling factor determina-
tions. Nevertheless, the model can be applied to many xenobiotics as
most are low extraction ratio compounds and passive diffusion gov-
erns their distribution into the liver.
Intrinsic Clearance. The experimental data failed to support two
critical assumptions of the ontogeny model (i.e., age-dependent
changes in intrinsic clearance reflect changes only in Vmax and KM
remains constant throughout development) (Alcorn and McNamara,
2002b). The data suggest a need to incorporate developmental
changes in KM estimates in the model-building process (i.e., model the
Vmax/KM ratio) instead of modeling only changes in Vmax. The incor-
poration of a new parameter, which undergoes interindividual vari-
ability during development, will increase the complexity of the model
and possibly result in greater uncertainty in its parameter estimates.
However, study design limitations may explain this apparent diver-
gence from model assumptions. Specifically, we question probe sub-
strate specificity in pediatric hepatic microsomal preparations. At best
probes are selective (not specific) for the P450 of interest (Kobayashi
et al., 2002; Lu et al., 2003), and selectivity is dependent upon
substrate concentration (Kato and Yamazoe, 1994). Since different
P450 enzymes undergo variable rates and patterns of development
(Borlakoglu et al., 1993; Rich and Boobis, 1997; Alcorn and Mc-
Namara, 2002a), P450 enzymes that contribute a small percentage to
probe metabolism in adult stages may play a larger role during
specific pediatric stages. In the study, differences in KM values may
reflect the contribution of other P450 enzymes, and the estimated KM
values will then reflect a hybrid of contributing enzymes. Eadie-
Hofstee plots (data not shown), though, gave no evidence of system-
atic deviation from a single site Michaelis-Menten model at higher
substrate concentrations for CZX, but curvilinear plots were observed
for MROD, suggesting the contribution of at least a second low-
affinity enzyme site. Furthermore, nonspecific binding to microsomal
protein (Obach, 1997; Obach et al., 1997) and differences in the
membrane environment of the endoplasmic reticulum (Dallner et al.,
1966) can influence apparent KM estimates. We cannot ignore the
potential for age-dependent changes in such factors. Although the data
do not rule out the possibility for developmental changes in the
inherent properties of P450s, we failed to find any information re-
garding changes in P450 enzyme active sites with postnatal matura-
tion. Further investigations are needed to explain these postnatal
changes in KM values. For example, recombinant P450s, singly ex-
pressed and mixed in proportion to P450 levels present in hepatic
microsomes at different age groups, may facilitate assessment of the
contribution of different P450 isoforms to the estimated KM value at
a given age (Tang et al., 2005).
The data on the age-dependent changes in CYP2E1 and CYP1A2
activity are consistent with the few reports of rat P450 ontogeny (Jahn
et al., 1993; Wu and Cederbaum, 1993; Rich and Boobis, 1997; Iba et
al., 2000; Anand et al., 2006). However, the observed lack of corre-
lation between developmental increases in P450 activity and immu-
noreactive protein levels violates an important model assumption.
Posttranslational modifications with development that markedly in-
fluence enzyme activity may explain the apparent discordancy. Alter-
natively, other P450 enzymes whose development precedes CYP2E1
and CYP1A2 maturation may contribute significantly to probe me-
tabolism at particular postnatal age stages. Finally, inadequate anti-
body specificity (i.e., cross-reactivity with other P450 enzymes) may
also contribute to this lack of congruence. For these reasons, P450
immunoreactive protein levels may not necessarily reflect enzyme
activity (Johnsrud et al., 2003). Interestingly, immunohistochemical
analysis revealed homogeneous expression of CYP1A2 and CYP2E1
in the hepatic acinus in fetal and early postnatal livers with increasing
preferential localization of CYP1A2 and CYP2E1 expression in
perivenous hepatocytes with postnatal development (Elbarbry et al.,
2007). With intrasinusoidal gradients in oxygen tension and substrate
supply, age-dependent changes in intrahepatic P450 expression pat-
terns will likely have some influence on P450 regulation and activity.
Further investigations into antibody specificity, involvement of alter-
native P450 enzymes in probe substrate metabolism and the role of
developmental changes in intrahepatic P450 expression patterns are
necessary to explain the lack of correlation between probe substrate
activity (Vmax estimates) and immunoquantifiable P450.
Finally, we observed that the activity of two different probe sub-
strates for each P450 covaried as a function of age, thus satisfying an
important model assumption. However, activity was generally de-
tected earlier with the less specific P450 substrate, which suggests the
involvement of additional P450 enzymes. Although the data do not
necessarily refute an implicit assumption of the ontogeny model,
namely, the infant shares the same metabolic pathways as the adult, it
does suggest that the relative contribution of different pathways
involved in the metabolism of a particular substrate may have varied
importance during development. This will influence both qualitative
and quantitative predictions, and the model will need to accommodate
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FIG. 6. ISF as a function of age for CYP1A2 (closed circles) and CYP2E1 (open
circles). ISF values were calculated from the product of HSF and Vmax values of
methoxyresorufin and chlorzoxazone for CYP1A2 and CYP2E1, respectively, at
each age group normalized to the adult values. Variability is represented as a
coefficient of variation of ratio data (see eq. 3).
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the potential for P450s to have different contributions at different
stages of development.
Conclusion
The data identified several important inconsistencies with the un-
derlying assumptions of the P450 ontogeny model. The observed
age-related changes in hepatic microsomal protein content suggest a
need to incorporate its developmental change into the modeling pro-
cess. Inconstant KM values during early postnatal development may
reflect questionable probe substrate specificity during P450 ontogeny
rather than age-dependent changes in the inherent properties of sub-
strate-P450 interactions. Further investigations are needed to deter-
mine the reason for age-dependent changes in the apparent KM values.
Consistent with model assumptions, the apparent Vmax estimates in-
creased postnatally to reach a maximum before or during weaning,
and the activity of two separate substrates for a given P450 covaried
as a function of age. The lack of correlation between age-dependent
changes in Vmax estimates and immunoreactive P450 requires further
investigation. Future studies are planned to 1) explain the incongru-
ence between the experimental data and several model assumptions
and 2) to develop a model of rat P450 ontogeny that provides rea-
sonable predictions of in vivo intrinsic clearance of P450 probe
substrates.
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